Drugs / tanastrozole
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05431504 Background | Jun 2022 → Dec 2025 overdue | female breast carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tanastrozole | “Endocrine therapy including but not limited to fulvestran, tanastrozole, letrozole or exemestane In regular doses” NCT05431504 ↗ |